NASDAQ:BYSI 延时15分钟

成交量

Lan Huang: Lan Huang is the founder of Dalian Wanchun Biotechnology Co. Ltd. (2010), Paramax International, Inc. (2008), BeyondSpring, Inc. (2013), and Wuxi Mtlh Biotechnology Co. Ltd. (2007). Dr. Huang is also the founder of Hubei Wanchun Biotechnology Co. Ltd., Seed Therapeutics, Inc., Seed Therapeutics, Inc. (Pennsylvania). Current jobs include Chairman & Chief Executive Officer at BeyondSpring Pharmaceuticals, Inc. and Director at Sincere Efforts Foundation, Inc. Former job includes Trustee at Lawrence University (2012-2015). Education includes an undergraduate degree from Lawrence University and a doctorate from the University of California, Berkeley.

Matthew Kirkby: Matthew Kirkby currently works at BeyondSpring, Inc., as Independent Director from 2016. Mr. Kirkby also formerly worked at CIMB Bank Bhd. (Hong Kong), as CEO-North Asia & Co-Head-Investment Banking from 2012 to 2015, NatWest Group Plc, as MD & Head-Global Banking Asia Pacific from 2010 to 2012, The HongKong & Shanghai Banking Corp. Ltd., as Head-Corporate Banking Asia Pacific from 2015 to 2016, and NatWest Markets Plc, as Head-Global Banking Asia Pacific from 2008 to 2012. Mr. Kirkby received his graduate degree from Pembroke College Oxford.

Patrick Fabbio: Patrick Fabbio currently works at BeyondSpring, Inc., as Independent Director from 2018 and Protara Therapeutics, Inc., as Chief Financial Officer from 2023. Mr. Fabbio also formerly worked at NPS Pharmaceuticals, Inc., as Vice President-Finance from 2012 to 2015, Biomatrix, Inc., as Controller, Progenics Pharmaceuticals, Inc., as Chief Financial Officer, Secretary & Senior VP, Ikano Therapeutics, Inc., as Chief Financial Officer from 2009 to 2011, Coopers & Lybrand (London), as Auditor, Catalent Pharma Solutions, Inc., as Vice President-Finance, Innovation & Growth, electroCore, Inc., as Chief Financial Officer, WindMIL Therapeutics, Inc., as Chief Financial Officer from 2020 to 2021, and Rafael Holdings, Inc., as Chief Financial & Accounting Officer in 2023. Mr. Fabbio received his undergraduate degree from Pace University and Masters Business Admin degree from The Leonard N Stern School of Business.

Brendan Delaney: Brendan Delaney currently works at BeyondSpring Pharmaceuticals, Inc., as Director, BeyondSpring, Inc., as Independent Director from 2021, and MJH Healthcare Holdings LLC, as Director. Mr. Delaney also formerly worked at Aadi Subsidiary, Inc., as President & Chief Executive Officer, Whitehawk Therapeutics, Inc., as President, Chief Executive Officer & Director in 2023, Novartis Oncology, Inc., as Director-Global Chronic Myeloid Leukemia Franchise from 2006 to 2011, Celgene Corp., as VP-US Commercial Hematology & Oncology, Immunomedics, Inc., as Chief Commercial Officer from 2017 to 2021, and Constellation Pharmaceuticals, Inc., as Chief Commercial Officer in 2021. Mr. Delaney received his undergraduate degree from Rutgers State University of New Jersey and Masters Business Admin degree from The Leonard N Stern School of Business.

Jiang Wen Majeti: Jiang Wen Majeti currently works at The Chinese-American Biopharmaceutical Society, as Director, BeyondSpring, Inc., as Independent Director from 2022, and Beta Gamma Sigma, Inc., as Member. Dr. Majeti also formerly worked at BioDuro LLC, as Senior Director-Business Development, The BayHelix Group, as Member, and Erasca, Inc., as Head-Global Collaborations. Dr. Majeti received her doctorate degree from the University of Wisconsin, undergraduate degree from Fudan University, and Masters Business Admin degree from Leavey School of Business.

Si Hai Xu: Si Hai Xu currently works at BeyondSpring, Inc., as Independent Director from 2022. Mr. Xu also formerly worked at Luoyang Chundu Group Co. Ltd., as Finance Director and Henan Plastic Surgery Hospital Co. Ltd., as Chief Financial Officer. Mr. Xu received his Masters Business Admin degree from Renmin University of China and undergraduate degree from Henan University of Economics & Law.

万春医药